• Doximity, Inc. recently presented at the ViVE 2026 conference in Los Angeles, where co-founder and CEO Jeffrey A. Tangney outlined the company’s latest digital healthcare tools and platform capabilities for medical professionals.
• This appearance, alongside upbeat analyst commentary on Doximity’s role in telemedicine and clinician workflow, has sharpened investor focus on its position in digital healthcare.
• Next, we’ll explore how this heightened attention on Doximity’s telemedicine and workflow platform could influence the company’s existing investment narrative.

AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Doximity Investment Narrative Recap

To own Doximity, you need to believe its telemedicine and clinician workflow tools can stay essential for U.S. doctors while it gradually monetizes newer AI features without eroding engagement. The ViVE 2026 appearance reinforces its profile with clinicians and clients, but does not materially change near term catalysts or the biggest risks around monetizing AI tools and managing exposure to pharma marketing budgets.

Against this backdrop, the fresh US$500 million share repurchase authorization on 5 February 2026 stands out. For existing shareholders, this capital return sits alongside interest in Doximity’s telemedicine and workflow platform and may matter more to the near term narrative than a single conference appearance, since buybacks can influence per share metrics even if revenue growth from new products takes longer to show up.

Yet beneath the product excitement, rising regulatory and policy uncertainty remains a risk investors should be aware of if...

Doximity's narrative projects $805.8 million revenue and $280.5 million earnings by 2028. This requires 11.0% yearly revenue growth and about a $45 million earnings increase from $235.1 million today.

Uncover how Doximity's forecasts yield a $63.57 fair value, a 147% upside to its current price.

Exploring Other Perspectives

While ViVE 2026 spotlights product momentum, the most bearish analysts caution that rising competition could compress margins, even as they still penciled in about US$756.2 million of revenue and US$266.6 million of earnings by 2028, reminding you that opinions on Doximity’s future can differ sharply and may shift again as new information comes in.

Explore 9 other fair value estimates on Doximity - why the stock might be worth just $25.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Doximity research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.